New combo therapy aims to boost esophageal cancer survival
NCT ID NCT07359443
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new approach for people with a type of esophageal cancer. Participants receive standard chemotherapy followed by a special MRI-guided radiation treatment. The main goal is to find the safest radiation dose and see if this combination can better control the tumor before surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA - GASTROESOPHAGEAL JUNCTION (GEJ) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Medical Center Utrecht
RECRUITINGUtrecht, Utrecht, 3582CX, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a swallowed balloon unlock the genetic secrets of esophageal cancer?
- Pulsing radiation may spare esophageal cancer patients from agonizing throat pain
- Personalized radiation pulses could boost esophageal cancer treatment
- Could a dye and camera spare esophageal cancer patients from extensive lymph node removal?
- Which biopsy method best spots early esophageal cancer?
- Can a simple blood test predict leukemia risk after cancer therapy?